

Dopamine Agonists Global Market Trends, Research, and Development - Market Shares, Segments and Insights up to 2034

*The Business Research Company's
Dopamine Agonists Global Market Report
2025 – Market Size, Trends, And Global
Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, May 27, 2025

/EINPresswire.com/ -- The [dopamine
agonists market size](#) has grown

significantly in recent years. The market is projected to grow from \$2.57 billion in 2024 to a substantial \$2.76 billion in 2025, equating to a compound annual growth rate CAGR of 7.7%. The vigorous growth in the historical period can be primarily attributed to factors such as the escalating occurrence of Parkinson's disease, increased diagnosis of restless legs syndrome RLS, broadening of reimbursement coverage, magnified CNS disorder research funding, and heightened healthcare awareness.

“

The Business Research
Company's Latest Report
Explores Market Driver,
Trends, Regional Insights -
Market Sizing & Forecasts
Through 2034

”

*The Business Research
Company*

The Business
Research Company

The Business Research Company



What's Fueling The Growth Of The [Dopamine Agonists
Market](#) Going Forward?

Looking to the future, the market is projected to see strong growth. It is estimated to reach \$3.69 billion by 2029, with a compound annual growth rate CAGR of robust 7.5%. Market growth can be largely attributed to factors such as a surge in the prevalence of neurological disorders, aging

global population, accelerating research and clinical trials, expansion of combination therapies, as well as rising awareness and diagnosis rates.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23375&type=smp>

What Are The Driving Forces And Trends For Dopamine Agonists Market?

Key trends set to shape the dopamine agonists market through the forecast period include advancements like personalized medicine and genetic profiling, wearable drug delivery systems, the use of AI and machine learning in drug development, extended-release formulations, and nanotechnology for drug delivery.

With the rise in the prevalence of neurological disorders, a notable growth trend is in the offering for the dopamine agonist market. Neurological disorders, conditions affecting the brain, spine, or nerves, often result in issues with movement, thinking, or behavior. The surging prevalence of these disorders can be partly attributed to increased life expectancy, since the risk for diseases like Parkinson's and Alzheimer's increases with age. In the therapeutic treatment of such disorders, dopamine agonists play a crucial role as they stimulate dopamine receptors in the brain, thus yielding better control and reduced symptoms.

Who Are The Key Industry Players In The Dopamine Agonists Market?

Notable entities operating in the dopamine agonists market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/dopamine-agonists-global-market-report>

What Are The Key Innovations In The Dopamine Agonists Market?

Major companies are focusing on innovations like flexible-dose monotherapy to reduce side effects and improve patient adherence, consequently offering more personalized treatment options for neurological disorders. Flexible-dose monotherapy allows doctors to adjust doses to meet each patient's specific needs and response to the drug. A noteworthy instance is AbbVie Inc., which, in November 2024, announced positive topline results from its Phase 3 TEMPO-2 trial. This trial demonstrated that the flexible-dose monotherapy tavapadon significantly improved motor function in early Parkinson's disease patients.

How Is The Dopamine Agonists Market Segmented?

Market segmentation includes:

1 By Product Type: Ergot Based Dopamine Agonists Market and Non-Ergot Based Dopamine Agonists Market

2 By Route of Administration: Oral, Parenteral, Transdermal Patches

3 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

4 By Application: Parkinson's Disease, Restless Legs Syndrome RLS, Hyperprolactinemia

5 By End User: Hospitals, Clinics, Home Care Settings

Subsegments:

1 Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide

2 Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine.

Which Regions Are Dominating The Dopamine Agonists Market?

In 2024, North America was the largest region in the dopamine agonists market. However, Asia-Pacific is projected to be the fastest-growing region in the forecast period. The regions covered in this report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

[About The Business Research Company](#)

The Business Research Company prides itself on comprehensive, data-rich research and insights, backed by over 15000+ reports across 27 industries that cover 60+ geographies. The company provides unique insights drawn from industry leaders based on 1,500,000 datasets and in-depth secondary research. Equipped with such robust information, you can stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/816362090>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.